Literature DB >> 1580602

Quinolone antimicrobial agents.

H C Neu1.   

Abstract

This chapter reviews the chemistry, microbiology, pharmacology, and clinical use of the fluoroquinolone antimicrobial agents. The molecular and clinical problems of bacterial resistance are reviewed. The clinical areas in which fluoroquinolones have been investigated are detailed, with particular attention to areas of appropriate and inappropriate use.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1580602     DOI： 10.1146/annurev.me.43.020192.002341

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN： 0066-4219            Impact factor:   13.739


  21 in total

Review 1.  The future of the quinolones.

Authors:  V T Andriole
Journal:  Drugs       Date:  1993       Impact factor: 9.546

2.  Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders.

Authors:  Barton L Wise; Christine Peloquin; Hyon Choi; Nancy E Lane; Yuqing Zhang
Journal:  Am J Med       Date:  2012-09-28       Impact factor: 4.965

3.  Multiple antibiotic resistance in Stenotrophomonas maltophilia.

Authors:  A Alonso; J L Martínez
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 4.  Quinolones in children. Are concerns over arthropathy justified?

Authors:  R Stahlmann; C Förster; D Van Sickle
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606

Review 5.  Genetics of Borrelia burgdorferi.

Authors:  Dustin Brisson; Dan Drecktrah; Christian H Eggers; D Scott Samuels
Journal:  Annu Rev Genet       Date:  2012-09-04       Impact factor: 16.830

6.  Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials.

Authors:  Aditi Mulgaonkar; Jürgen Venitz; Dirk Gründemann; Douglas H Sweet
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

7.  In vitro activity of the new fluoroquinolone CP-99,219.

Authors:  H C Neu; N X Chin
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

8.  A pyrimido[1,6-a]benzimidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potential.

Authors:  A H Corbett; P Guerry; P Pflieger; N Osheroff
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

9.  Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora.

Authors:  M Ritz; H Lode; M Fassbender; K Borner; P Koeppe; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  A randomised, multinational study with sequential therapy comparing ciprofloxacin twice daily and ofloxacin once daily.

Authors:  H Bassaris; E Akalin; S Calangu; R Kitzes; J Kosmidis; M Milicevic; H Noack; R Raz; E Salewski; M Sukalo
Journal:  Infection       Date:  1995 Jul-Aug       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.